Precision Medicine in Oncology

The AJMC^® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

By Mary Caffrey

August 16th 2023

ASCO 2023: Solid Tumors

By Mary Caffrey
Peter Page

July 31st 2023

Cathy Eng, MD

FDA Sets Priority Review for Fruquintinib as ASCO Data Confirm Safety Results

By Mary Caffrey

June 20th 2023

Conversations on Equity in Cancer Care: Meet the Leaders of NCCN’s DEI Directors Forum

By Interview by Matthew Gavidia

April 17th 2023

David Jackman, MD

David Jackman, MD, on Clinical Pathway Buy-in, Process for Updates

By Hayden E. Klein

February 23rd 2023

More News

FCM, NGS, and PCR, Oh My! Detecting MRD in Patients With Acute Lymphoblastic Leukemia

February 15th 2020

FCM, NGS, and PCR, Oh My! Detecting MRD in Patients With Acute Lymphoblastic Leukemia

Flow cytometry (FCM), next-generation sequencing, (NGS), and polymerase chain reaction (PCR) are the 3 most common methods clinicians use to diagnose minimal residual disease (MRD) in patients with acute lymphoblastic leukemia who have undergone chemotherapy, radiotherapy, or immunotherapy. MRD can be found both in bone marrow via aspiration and peripheral blood circulation through a draw.

Genetic Variant Linked to Poor Advanced Prostate Cancer Outcomes

February 13th 2020

Genetic Variant Linked to Poor Advanced Prostate Cancer Outcomes

A testosterone-related genetic variant (HSD3B2[1245C]) is linked to poor outcomes in advanced prostate cancer, according to a recent study published in JAMA Oncology.

Viraj Narayanan: Real-World Data Are Not Going to Replace Clinical Trials

February 10th 2020

Viraj Narayanan: Real-World Data Are Not Going to Replace Clinical Trials

Instead of replacing clinical trials, real-world data will be used to supplement traditional clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.

CAR NK Cells Demonstrate Encouraging Preliminary Results, Study Shows

February 6th 2020

CAR NK Cells Demonstrate Encouraging Preliminary Results, Study Shows

Anti-CD19 chimeric antigen receptor natural killer (CAR NK) cells, derived from donor umbilical cord blood, produced a 73% objective response rate in 11 patients with lymphoid tumors who received just 1 dose of the infused therapy, with no occurrences of cytokine release syndrome or neurotoxicity, in preliminary study results out of MD Anderson. Seven patients had a complete remission.

Viraj Narayanan Discusses the Impacts of Real-World Data on Clinical Research

February 3rd 2020

Viraj Narayanan Discusses the Impacts of Real-World Data on Clinical Research

The integration of real-world data into clinical research may mark a shift away from clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.

This Week in Managed Care: January 31, 2020

February 1st 2020

This Week in Managed Care: January 31, 2020

This week, top managed care stories included a new plan for Medicaid block grants; federal officials’ response to the novel coronavirus; FDA offers guidance for gene therapies.

Reengineering CAR T Cells to Optimize Their Powers

January 30th 2020

Reengineering CAR T Cells to Optimize Their Powers

Chimeric antigen receptor (CAR) T cells are a patient’s own, harvested and reengineered to attack specific malignant cells. They were initially developed using knowledge gleaned from allogeneic stem cell transplants: that donor mature immune cells can attack healthy cells in the recipient patient.

CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers

January 28th 2020

CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers

Allison Inserro Mary Caffrey

CMS said it is expanding coverage of next generation sequencing (NGS) for use as a diagnostic for patients with germline breast and ovarian cancer, paving the way for Medicare beneficiaries to receive more personalized medicine. However, an advocate said the wording of CMS' decision could actually limit testing access for some women with breast or ovarian cancer.

MRD Status an Important Prognostic Factor in Pediatric B-Lymphoblastic Leukemia, Study Says

January 24th 2020

MRD Status an Important Prognostic Factor in Pediatric B-Lymphoblastic Leukemia, Study Says

Minimal residual disease (MRD), a measure of how many cancer cells remain in a patient during or following chemotherapy or stem cell transplant, is a potent indicator of whether or not a patient is likely to relapse; recent research probed the associations between MRD status and certain prognostic risk factors in childhood B-lymphoblastic leukemia after both induction and consolidation.

Dr Stuart Goldberg: Biomarkers and Genomic Testing Can Impact Cancer Care

January 24th 2020

Dr Stuart Goldberg: Biomarkers and Genomic Testing Can Impact Cancer Care

Several barriers exist when it comes to effectively integrating genomic testing and biomarkers into cancer testing and care, said Stuart Goldberg, MD, Chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center at Hackensack University Medical Center.

Dr C. Ola Landgren on Getting Groundbreaking Research Into the Clinic Faster

January 23rd 2020

Dr C. Ola Landgren on Getting Groundbreaking Research Into the Clinic Faster

Minimal residual disease (MRD) may be prevalent in clinical trials and discussed at conferences, but it is not really used widely in practice, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.

Quality of Life Improvement With Docetaxel Plus Plinabulin Versus Pegfilgrastim

January 18th 2020

Quality of Life Improvement With Docetaxel Plus Plinabulin Versus Pegfilgrastim

The small molecule from BeyondSpring is currently in late-stage clinical development in non–small cell lung cancer and for prevention of chemotherapy-induced neutropenia.

clonoSEQ Assay Medicare Coverage Expanded to Include MRD in CLL

January 14th 2020

clonoSEQ Assay Medicare Coverage Expanded to Include MRD in CLL

clonoSEQ, from Adaptive Biotechnologies, is a next-generation sequencing assay with existing Medicare coverage to monitor for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia. The newest Medicare coverage is for chronic lymphocytic leukemia (CLL), which takes effect immediately.

Blueprint Medicines' Ayvakit Approved for Rare GIST With PDGFRA Mutation

January 10th 2020

Blueprint Medicines' Ayvakit Approved for Rare GIST With PDGFRA Mutation

The platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation occurs in close to 6% of patients with gastrointestinal stromal tumors (GIST), the most common being the D842V mutation, for which there is no effective, approved treatment. The drug previously received breakthrough therapy, fast track, and orphan drug designations.

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

January 8th 2020

Dr C. Ola Landgren: MRD Is a Growing Topic of Interest in Cancer

While minimal residual disease (MRD) has been a topic of research for at least a decade, right now it is more top of mind than ever before for people treating cancer, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.

January 8th 2020

The Democratization of Precision Medicine: A Clinician's Perspective on the Future of Oncology Care - Q&A With Neil Vasan, MD, PhD

January 8th 2020

Laboratory Logistics: An Operational Perspective on Precision Medicine - Q&A With Claudia French

January 8th 2020

The Importance of the Clinician-Pathologist Relationship in Precision Oncology - Q&A With Ryan K. Olson, MD

January 8th 2020

The Value of Decision Support Teams and Payer-Institution Partnerships in Precision Oncology - Q&A With Kenna R. Mills Shaw, PhD

January 8th 2020

Forging Diagnostic Pathways for Optimal Utilization of Precision Medicine in Oncology - Q&A With R. Steven Paulson, MD

January 8th 2020

How Advances in Precision Oncology Are Shaping a New Diagnostic and Treatment Frontier

Partnership Seeks to Offer Combined Somatic, Germline Testing to Guide Cancer Treatment

January 7th 2020

Partnership Seeks to Offer Combined Somatic, Germline Testing to Guide Cancer Treatment

Caris Life Sciences, a leader in somatic testing on cancer tumor cells, has joined forces with Ambry Genetics to offer its 67-gene test that evaluates a patient’s hereditary risk for cancer.

Study Suggests Epigenetic Therapy May Help Subgroup of Patients With Marginal Zone Lymphoma

January 6th 2020

Study Suggests Epigenetic Therapy May Help Subgroup of Patients With Marginal Zone Lymphoma

Alison Rodriguez

Epigenetic drug therapy should be explored for certain patients with marginal zone lymphoma, according to a recent study.

Dr Lindsey Roeker on Using MRD for Decision Making

December 29th 2019

Dr Lindsey Roeker on Using MRD for Decision Making

So far, minimal residual disease (MRD) has not been used much outside of clinical trials, but researchers are testing how it might be used to guide decisions in clinical practice, said Lindsey Roeker, MD, clinical fellow at Memorial Sloan Kettering Cancer Center.

Dr Michael Wang on the Coming Precision Medicine Era in Mantle Cell Lymphoma

December 27th 2019

Dr Michael Wang on the Coming Precision Medicine Era in Mantle Cell Lymphoma

The next era in treating mantle cell lymphoma will use precision medicine to target therapies in a personalized way, said Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson.

Researchers Report on Use of Nanopore Technology to Detect AML Biomarkers

December 23rd 2019

Researchers Report on Use of Nanopore Technology to Detect AML Biomarkers

Sara Karlovitch

Nanopore technology, still in its developmental phases, could be used to detect predictive biomarkers for acute myeloid leukemia (AML), according to a recent study.

Biomarker Use in Colorectal Cancer

December 18th 2019

Biomarker Use in Colorectal Cancer

Despite a 20% drop in mortality since 2009, colorectal cancer accounted for 9.8% (881,000) of deaths worldwide in 2018 and represents 10.2% of all cancer cases worldwide. It is No. 3 on the list of most prevalent cancers worldwide—1.8 million new cases in 2018—behind only lung cancer and breast cancer.

Dr Rita Nanda on Using Precision Medicine to Scale Back on Chemotherapy Treatments in Breast Cancer

December 16th 2019

Dr Rita Nanda on Using Precision Medicine to Scale Back on Chemotherapy Treatments in Breast Cancer

Although the pembrolizumab 8 arm of I-SPY2 did not have strong enough results to continue onto phase 3, it does provide some insights and highlights the need for precision medicine to tailor approaches to treatment, said Rita Nanda, MD, associate professor, medicine, The University of Chicago Medicine.

The Value of Genomic Profiling for Women With Breast Cancer

December 15th 2019

The Value of Genomic Profiling for Women With Breast Cancer

Laura Joszt, MA

Findings from 2 studies presented at the San Antonio Breast Cancer Symposium highlight the value of genomic profiling for women with breast cancer.

At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow

December 14th 2019

At Increasing Levels of Sensitivity, NGS-MRD Detects CLL in Bone Marrow

A study presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, discussed the first report of next-generation sequencing (NGS) to test for minimal disease response (MRD) after the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) in chronic lymphocytic leukemia (CLL).

...

4 5 6 7 8 9 10 11 12 13 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions